In a new study, researchers led by Dr. Aaron Cypess from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) examined whether a drug called mirabegron could increase brown fat activity in healthy women.
Mirabegron is currently approved by the Food and Drug Administration (FDA) for a condition called overactive bladder. The drug binds to a protein on the surface of cells that’s thought to also stimulate brown fat and improve the ability of white fat to break down and release its stored fat into the bloodstream.